

TATA**NIFTY MIDSMALL
HEALTHCARE INDEX FUND**(An open-ended scheme replicating/tracking Nifty MidSmall Healthcare Index (TRI))**TATA**
mutual fund

India's 1st MidSmall Healthcare Index Fund

INVEST IN THE INDUSTRY THAT IS

A LIFELINE FOR BILLIONS



HEALTHCARE ON THE RISE

Lollapalooza Effect

(In extreme outcome caused by a combination of factors moving in the same direction. When multiple forces are all operating in the same direction, then result is not linear but exponential)

Convergence of five driving factors


Better cashflow position of domestic
pharma companies

High margins leading to better profitability
of domestic pharma companies

Pricing pressure of drugs in US market has
stabilized

Revenue per bed of hospitals
increasing

Increasing health awareness making a case
for Diagnostics, Research and other Health
services



Source: AMFI classification, Internal Research

Domestic market - Refers to Indian market.

Export/US market - Export bucket majorly dominated by US market. US is the biggest export market for India.

Active pharmaceutical ingredient (API) - It is the base ingredient contained in medicine.


Contract Manufacturing - These are companies that serve other companies in the pharmaceutical industry on a contract basis to provide comprehensive services from drug development to final product.

Formulation - These are categorized into branded & generic drugs. Generics drugs have generally basic packaging, labels, and lower priced than branded drugs.



Healthcare as a % of GDP

Healthcare spend increases significantly, as GDP per capita increases. Developed economies have a very high expenditure on Healthcare as % of GDP in comparison to developing economies which gives India a headroom for growth.



Source : World Bank

Pharmaceutical Industry

The growth attributes for the Pharmaceutical market are;

- » Demand for both acute and chronic segments
- » Price revision by pharma companies
- » Launch of new product etc
- » Easing of pricing pressures
- » Revitalization of biotech funding
- » Launch of specialty products
- » Deeper penetration in the generic market.


Growth of Pharma Exports (in US\$ billion)



Hospital Industry


The industry reported a healthy CAGR of 10-11%. Over the next three fiscal years, the growth is expected to contribute at a healthy CAGR of approximately 12%.

Revenue per Hospital bed - Hospitals improving on high-end specialty treatment, annual price revisions by companies to offset cost inflation, rising awareness of insurance benefits, will support positively to revenue to expand further.



The figures are in lakh crore.

Source: Care Ratings




The figures are in Rs.

Source: Care Ratings

Nifty Midsmall Healthcare Index Market cap breakup

30 stocks (selected from Nifty MidSmallcap 400)




*Healthcare stocks considered (based on 6-month average free float market capitalization)

*Stocks belonging to Nifty 100 index are Large cap, Stocks belonging to Nifty Midcap 150 index are Mid cap and Stocks belonging to Nifty Smallcap 250 index are Small cap

Data as on 30th June 2025

Nifty Midsmall Healthcare Index Constituents - Basic Industry



Methodology

- The Nifty MidSmallcap healthcare index is designed to reflect the behavior and performance of the Healthcare companies.
- Stocks forming part or going to form part of Nifty MidSmallcap 400 index at the time of review are eligible for inclusion in the index.
- The companies are sorted in the descending order of last 6 months average free-float market capitalization and final selection of companies in the Index shall be made based on the order of Free Float market capitalization.
- Stock weights shall be capped at 33% each and the aggregate weight of top 3 stocks shall be capped at 62% at the time of index rebalancing.
- The review and reconstitution of the Index is undertaken semi-annually.

Index Performance (as on 31st May 2025)

Index Name	1 year	3 years	5 years	10 years	Since April 2024
Nifty MidSmall Healthcare Index	20.50	NA	NA	NA	22.32
Nifty MidSmall Healthcare TRI	22.19	NA	NA	NA	24.28

Holdings (as on 30th June 2025)

NAME OF THE INSTRUMENT	% TO NAV
Max Healthcare Institute Ltd.	16.04
Lupin Ltd.	7.93
Fortis Healthcare Ltd.	7.00
Aurobindo Pharma Ltd.	5.37
Laurus Labs Ltd.	4.80
Alkem Laboratories Ltd.	4.49
Glenmark Pharmaceuticals Ltd.	4.47
Mankind Pharma Ltd	4.43
Biocon Ltd.	3.61
Ipca Laboratories Ltd.	3.27
Abbott India Ltd.	3.15
Krishna Institute Of Medical Sciences Ltd.	2.80
Narayana Hrudayalaya Ltd.	2.49
Gland Pharma Ltd.	2.47
Glaxosmithkline Pharmaceuticals Ltd.	2.37

NAME OF THE INSTRUMENT	% TO NAV
J.b.chemicals & Pharmaceuticals Ltd.	2.30
Aster Dm Healthcare Ltd.	2.27
Piramal Pharma Ltd	2.13
Cohance Lifesciences Ltd.	2.09
Syngene International Ltd.	2.05
Ajanta Pharma Ltd.	1.83
Dr. Lal Path Labs Ltd.	1.77
Neuland Laboratories Ltd.	1.74
Global Health Ltd.	1.62
Pfizer Ltd.	1.46
Poly Medicure Ltd.	1.44
Natco Pharma Ltd.	1.40
Rainbow Childrens Medicare Ltd.	1.32
Granules India Ltd.	1.21
Alembic Pharmaceuticals Ltd.	0.98

Highlights of the Scheme


Scheme Name	Tata Nifty MidSmall Healthcare Index Fund
Investment Objective	The investment objective of the scheme is to provide returns, before expenses, that are in line with the performance of Nifty MidSmall Healthcare Index (TRI), subject to tracking error. However, there is no assurance or guarantee that the investment objective of the Scheme will be achieved. The scheme does not assure or guarantee any returns.
Type Of Scheme	An open-ended scheme replicating/tracking Nifty MidSmall Healthcare Index (TRI).
Fund Manager	Kapil Menon
Benchmark	Nifty MidSmallcap Healthcare index
Min. Application Amount (During NFO)	Rs 5,000/- and in multiple of Re. 1/- thereafter
Load Structure	Entry Load: NIL Exit Load: 0.25% of the applicable NAV, if redeemed on or before 15 days from the date of allotment.

This product is suitable for investors who are seeking*:


- Long Term Capital Appreciation.
- Investment in equity and equity related instruments comprised in Nifty MidSmall Healthcare Index.

***Investors should consult their financial advisors if in doubt about whether the product is suitable for them**

Scheme Risk-O-Meter



Benchmark Risk-O-Meter



It may be noted that risk-o-meter specified above is based on internal assessment. The same shall be updated as per provision no. 17.4.1.i of SEBI Master Circular on Mutual Fund dated 27.06.2024, on Product labelling in mutual fund schemes on ongoing basis.

Mutual Fund investments are subject to market risks, read all scheme-related documents carefully.